BioAffinity Debt To Equity from 2010 to 2024

BIAFW Stock  USD 0.72  0.03  4.00%   
BioAffinity Technologies Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.09477793
Current Value
0.0995
Quarterly Volatility
0.43378985
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 262.1 K, Interest Expense of 35.3 K or Gross Profit of 831.2 K, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0 or PTB Ratio of 2.78. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
  
Check out the analysis of BioAffinity Technologies Correlation against competitors.

Latest BioAffinity Technologies' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of bioAffinity Technologies Warrant over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. BioAffinity Technologies' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.00 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

BioAffinity Debt To Equity Regression Statistics

Arithmetic Mean(0.74)
Geometric Mean0.54
Coefficient Of Variation(58.59)
Mean Deviation0.34
Median(0.99)
Standard Deviation0.43
Sample Variance0.19
Range1.0934
R-Value0.79
Mean Square Error0.08
R-Squared0.62
Significance0.0005
Slope0.08
Total Sum of Squares2.63

BioAffinity Debt To Equity History

2024 0.0995
2023 0.0948
2022 0.0228
2021 -0.72
2020 -0.66

About BioAffinity Technologies Financial Statements

BioAffinity Technologies investors use historical fundamental indicators, such as BioAffinity Technologies' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.09  0.10 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.